Drug Approval | July 24, 2024
Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Subscribe To Our Newsletter & Stay Updated
